Forefront Analytics’s Eiger BioPharmaceuticals EIGR Stock Holding History
Bought
Maintained
Sold
Other funds holding EIGR
6CM
Forefront Analytics's EIGR Position: Q2 2023 in Review
Forefront Analytics sold out of Eiger BioPharmaceuticals (EIGR) in Q2 2023, closing a stake of 1,723 shares — an estimated $46.3K sold.
Forefront Analytics first reported a position in EIGR in Q1 2021 and held it in 8 quarters. The position peaked at $97K in Q1 2021. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.
- Forefront Analytics reported no remaining Eiger BioPharmaceuticals position as of Q2 2023 after selling out during the quarter.
- Forefront Analytics sold 1,723 Eiger BioPharmaceuticals shares in Q2 2023, an estimated $46.3K.
- Forefront Analytics first reported a position in Eiger BioPharmaceuticals in Q1 2021 and held it in 8 quarters.
- Forefront Analytics's Eiger BioPharmaceuticals position peaked at $97K in Q1 2021.
- 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals as of Q2 2023.
Based on Forefront Analytics's 13F filing for Q2 2023, filed 11 Aug 2023.